BioAge Labs Forecast, price target & analysts
BioAge Labs Target price 2026 - Analyst rating & recommendation
BioAge Labs Classifications & Recommendation
BioAge Labs Price Target
| Target Price | $30.60 |
| Price | $6.81 |
| Potential |
349.34%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target BioAge Labs 2027 .
The average BioAge Labs target price is $30.60.
This is
349.34%
register free of charge
$76.65
1,025.55%
register free of charge
$20.20
196.62%
register free of charge
|
|
| A rating was issued by 15 analysts: 12 Analysts recommend BioAge Labs to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BioAge Labs stock has an average upside potential 2027 of
349.34%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 9.00 | 7.46 |
| 17.16% | ||
| EBITDA Margin | -1,028.56% | -1,662.50% |
| 61.63% | ||
| Net Margin | -895.67% | -1,522.24% |
| 69.96% |
12 Analysts have issued a sales forecast BioAge Labs 2026 . The average BioAge Labs sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an BioAge Labs EBITDA forecast 2026. The average BioAge Labs EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 BioAge Labs Analysts have issued a net profit forecast 2026. The average BioAge Labs net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.24 | -2.48 |
| 13.13% | 10.71% | |
| P/E | negative | |
| EV/Sales | 0.89 |
12 Analysts have issued a BioAge Labs forecast for earnings per share. The average BioAge Labs EPS is
This results in the following potential growth metrics and future valuations:
Current BioAge Labs Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Roth Capital |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Jul 31 2026 |
| Roth Capital |
Locked
➜
Locked
|
Locked | May 27 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | May 13 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Roth Capital:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Aug 03 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Jul 31 2026 |
|
Locked
Roth Capital:
Locked
➜
Locked
|
May 27 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
May 13 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
